- Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
- Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device
- Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the Fourth Quarter 2023; Raising 2024 Revenue Guidance
- Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3
- Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
- Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women’s Health
- Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics
- Myriad Genetics Names George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology
- Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics
- Myriad Genetics Applauds New Germline Testing Guideline for Patients with Breast Cancer from ASCO-SSO
More ▼
Key statistics
On Thursday, Myriad Genetics Inc (MYGN:NSQ) closed at 21.32, -11.94% below its 52-week high of 24.21, set on Jun 30, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 21.35 |
---|---|
High | 21.67 |
Low | 21.16 |
Bid | 16.20 |
Offer | 24.50 |
Previous close | 21.40 |
Average volume | 744.49k |
---|---|
Shares outstanding | 89.87m |
Free float | 87.72m |
P/E (TTM) | -- |
Market cap | 1.92bn USD |
EPS (TTM) | -3.20 USD |
Data delayed at least 15 minutes, as of Mar 28 2024 20:00 BST.
More ▼